Why a CLIA checklist has to be about architecture, not features
Most vendors selling clinical lab software treat CLIA as a set of screens. A sign-off screen, an audit log screen, and a QC screen. The screens demo well, and a surveyor does not look at screens. They look at whether the underlying record can be reconstructed and whether the controls can be walked around.
There is one distinction on which the rest of this checklist depends. A control enforced in the user interface is bypassed by a direct database write, an API call, or a UI bug. A control enforced in the schema and the service layer has no path around it, regardless of how the system is accessed. The first kind passes a sales demo. The second kind passes a survey. In a 45-minute vendor call, they look identical, which is why a checklist that only asks about features tells you nothing useful.
It is worth stating the penalty structure accurately, because the figure in most vendor decks is wrong. Under 42 CFR 493.1834(d), a condition-level deficiency that does not pose immediate jeopardy carries a civil money penalty of $50 to $3,000 per day. The real cost for most labs is not the daily figure. It is the directed plan of correction, the revisit, and the path toward suspension or revocation of the certificate that the lab needs in order to bill Medicare.
The 12-point checklist at a glance
Use these in a live conversation. You are listening for whether the answer points below the user interface or names a screen.
The 12-point CLIA software compliance checklist
Every reported result must be reconstructable from the chain that produced it: the instrument and run, the reagent lot, the QC that validated that run, the analyst who reviewed it, and the person who released it. 42 CFR 493.1291 governs the requirement that results move accurately and reliably from data entry to the final destination.
The links in that chain have to be structural. If the connection between a result and its instrument session is an application-maintained foreign key, a migration or a direct write can sever it without anyone noticing. If it is a schema constraint, it cannot be severed silently.
Walk me through how you trace one patient result from raw instrument output to the released report, and show me that lineage as a query my compliance team can run without engineering help.
Retention is not one number. Under 42 CFR 493.1105, most test and analytical system records must be retained for a minimum of 2 years. Pathology test reports run for at least 10 years. Histopathology slides run for at least ten years; cytology slide preparations for at least five. Immunohematology, blood, and transfusion records follow 21 CFR 606.160, which commonly means ten years and sometimes longer.
Retention has to be a tiered policy keyed to record classification, and records inside their window have to be deletion-protected so nothing, including an administrator account, can remove or alter them before the window closes. A team that built general healthcare systems usually applies a single flat retention rate, which under-retains long-tail categories and over-retains routine records.
Tell me your retention configuration for routine chemistry, for pathology, and for immunohematology, in those words. A single uniform answer is the disqualifier.
Each patient result must be linkable to the QC that validated its run, and when a QC failure is discovered after results are reported, every affected result must be identifiable.
QC linkage at the record level, not the run level, and an automatic flag on every patient result tied to a failed QC run. Manual reconciliation by staff is not a control, it is a liability that the next survey will find.
How does the system link a result to the QC run that validated it, and what happens to already-released results when a QC failure surfaces afterward?
A surveyor or accreditor can ask to see who changed a QC record and when, or every access to a specific result. The record they read has to be complete.
Every create, update, and delete is logged at the record level with timestamp, identity, and reason code, in an append-only storage that a system administrator cannot edit. Session-level or batch-level logging is not an audit trail; it is a summary that appears to be one until it is tested.
In these exact words: if one of your engineers writes directly to the production database, does the audit trail still capture it? The length of the pause is the answer.
Results may be released only by a licensed director or an authorized designee. The operative word is "only."
Release authorization enforced at the service layer, at the point the result actually leaves the system, not in a button on a screen that a different code path can skip. A report cannot reach an external destination without a logged authorization event tied to a credentialed identity.
Where is sign-off enforced — the UI, the service layer, or the schema — and how does the system stop a result from being released through an API that bypasses your interface?
An amendment must never overwrite the original result. Both the original and the correction have to be independently reportable at any future point.
Versioning has to be how the data model represents a result. An amendment generates a new version and the original is preserved and queryable. A platform that updates the row in place has destroyed evidence a surveyor is entitled to see.
When an amendment is filed, what happens to the original, and can you show me both in the same query?
Labs monitor and document turnaround time per test, and accreditors review TAT during surveys.
Every state transition in the specimen lifecycle timestamped at the moment it happens, captured at ingestion, with TAT reportable per test, per operator, and per ordering provider. TAT reconstructed after the fact from incomplete events is the TAT you cannot defend. This is also where clinical workflow automation earns its place, by catching a TAT or QC threshold breach in seconds instead of after a batch reveals it.
Can you produce a TAT compliance report by test type for an arbitrary date range, not just the current period?
Every result links to a credentialed operator, competency assessments are on file per test category, and a non-credentialed user must not be able to release a result.
A role registry that ties every result to a credentialed identity, with non-credentialed roles structurally blocked from release actions rather than hidden in the interface. "Must not be able to" is an architecture statement, not a UI one.
How does a non-credentialed role get blocked from release, and is that block in the data layer or just the screen?
Validation rigor varies by certificate class. A high-complexity lab under a Certificate of Accreditation has the heaviest validation and documentation burden; a waived or PPM setting has far less.
A partner who has only built for low-complexity settings will design a lighter validation approach than your accreditation requires, and you discover the gap during the survey rather than during the build.
Which certificate class do you design validation for, and can you produce a validation package from prior CLIA work?
The laboratory is responsible for the accuracy of every result reported, including data entering through instrument interfaces, integrations, and migrations.
Quality gates that run at the pipeline layer, where they can halt bad data before it reaches the patient record. A partner who validates data only when it is displayed has no mechanism to catch what enters through the back of the system.
Where in the pipeline do quality checks fire before data reaches the patient result, and how do operations staff find out when one fails?
A clinical lab data pipeline that stays accurate as instruments and connected systems change.
Standards-based integration using HL7 v2 and FHIR R4 with an abstraction layer, plus schema-drift detection that alerts when a connected system adds or changes a field, before that change corrupts traceability or retention downstream. Labs running multiple LIMS and analyzers from acquisitions and reference labs live with constant schema change; the pipeline has to expect it.
How does the integration layer handle a LIMS or instrument schema change, and what alerts before a downstream record is wrong?
Nothing directly, but accreditation, TAT, and QC review depend on the Lab Director and Clinical Operations Lead being able to see performance in time to act.
A governed reporting layer where a Lab Director can pull TAT by test category, QC pass rates by instrument and shift, and exception reports without filing a query request to engineering, and trust the numbers because they come from the same governed, CLIA-compliant record store.
Can our Lab Director pull a TAT and QC pass-rate report themselves, and is that data the same governed record that the rest of the system runs on?
Run the 12-point checklist against your current platform with a NonStop engineer. Pick one finalized result, we trace it end-to-end, and you get a written findings report.
Request a CLIA Architecture Review →How NonStop maps to this checklist
NonStop builds clinical lab and genomics platforms in regulated environments. The relevant point for this checklist is where the controls sit in what the firm ships, because that is the attribute a survey indirectly tests. The patterns below are from the CLIA engineering standard that NonStop adheres to.
An amendment generates a new version; the original is preserved and independently auditable, and there is no overwrite path in the schema for a later code path to find.
Enforced at the service layer. A report cannot reach an external destination without a logged authorization event tied to a director or designee, so an alternate code path has nothing to route around.
Append-only, recording every data mutation with a timestamp, user identity, and reason code. The engineer-writes-directly-to-the-database case is still captured, as the logging does not depend on the application reporting on itself. A compliance officer can reconstruct the lifecycle of any result without engineering involvement.
State transitions are timestamped at ingestion, with TAT reportable per test, per operator, and per ordering provider, and configurable alerting when a threshold is breached rather than after a batch reveals it.
Tiered, deletion-protected retention policies by record class, with HL7 v2 and FHIR R4 ingestion and schema-drift alerting across multiple LIMS and instruments.
The standard NonStop states for itself is that the data model enforces CLIA requirements — sign-off, versioning, and audit trails — rather than the UI layer, because that is what determines the outcome when a CMS or CAP inspector is on site. That sentence is easy to write and hard to build, which is exactly why the right move is to make any vendor prove it against the twelve points above rather than assert it in a deck.
What to do with this checklist
If you are selecting a partner for a clinical lab platform build, a laboratory information system product development engagement, or a legacy LIMS modernization, run the twelve questions in a live call. A firm that has shipped a CLIA-regulated system answers by pointing below the UI and telling you what broke in a real survey. A firm that has not answers with the feature name and the product tour. The difference does not show up in a demo. It shows up in a room with a surveyor, which is the most expensive place to learn it.
If you already run a platform, run point 4 on it yourself before CMS does. Pick one finalized result, try to reconstruct it end-to-end without engineering, then put the database-write question to your own team and time the answer.
Talk to NonStop
Talk to a CLIA Engineer
Inspection on the horizon, or a finding you need to close? Tell us the gap. A NonStop engineer will review your platform against the 12 points and provide a remediation plan you can hand to your Lab Director. We take a single finalized result and trace it through your current platform end-to-end against the twelve points and what a surveyor would actually ask, then give you a written account of where the reconstruction holds and where it breaks. No product tour — the deliverable is the findings.
Talk to a CLIA Engineer →